Raltegravir tablets launch: Proven benefits for patients
Raltegravir tablets launch offers a new treatment option for patients in the US with 180-day exclusivity.
Raltegravir tablets launch offers a new treatment option for patients in the US with 180-day exclusivity.
Stroke prevention drug news highlights Bayer’s first global approval in China, promising enhanced treatment options for patients.
Qftilia therapy approval is a significant advancement for haemophilia patients in India, ensuring better healthcare options.
FDA approval of WELTRUZA marks a significant achievement for Medincell in the pharmaceutical industry.
Milestone Pharmaceuticals stock remains steady at $0.92 following China approval, showing potential for growth in the pharmaceutical market.
As we grow older, our healthcare needs become more and more pressing. That’s why it’s essential to have comprehensive health insurance. And for those over…
